{
  "scan_date": "2026-02-28",
  "scan_time": "07:35",
  "version": "1.9.0",
  "stats": {
    "total_tickers": 60,
    "buy_signals": 0,
    "watchlist_signals": 9,
    "momentum_signals": 10,
    "tier1_qualified": 2,
    "tier2_qualified": 6,
    "growth_qualified": 6,
    "accel_qualified": 34,
    "quality_qualified": 27,
    "quality_winners": 29,
    "screener_candidates": 21,
    "convergence_signals": 20
  },
  "edge_buckets": [
    {
      "label": "WATCHLIST",
      "tickers": [
        "ADBE",
        "NBIS",
        "TTD",
        "AGI",
        "BRCTF",
        "GDDY",
        "IREN",
        "PYPL",
        "PLTR"
      ]
    },
    {
      "label": "MOMENTUM",
      "tickers": [
        "DSKYF",
        "SOFI",
        "CRWV",
        "MNKD",
        "ASTS",
        "AXSM",
        "REPL",
        "ETN",
        "DTE",
        "BMRN"
      ]
    }
  ],
  "opportunities": [
    {
      "ticker": "ADBE",
      "score": 91,
      "recommendation": "WATCHLIST",
      "profile": "value",
      "tier": 5,
      "confidence": 56,
      "price": 262.41,
      "market_cap_fmt": "$109.8B",
      "down_from_high_pct": 42.1,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 3.02,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "profitability": 20,
        "fcf": 20,
        "discount": 15,
        "sector_panic": 15,
        "pe_discount": 15,
        "no_dilution": 11,
        "convergence_bonus": 8,
        "news_boost": 6,
        "breakout_pattern_bonus": 14,
        "claude_enhancement": -8,
        "ai_disruption": 8,
        "insider_sell_penalty": -10
      },
      "score_trend": [
        111,
        86,
        84,
        88,
        97,
        98,
        97,
        90,
        96,
        91
      ],
      "price_trend": [
        258.61,
        258.61,
        246.68,
        256.595,
        256.595,
        255.17,
        257.81,
        259.04,
        259.04,
        262.41
      ],
      "trend_direction": "stable",
      "aggregate": {
        "avg_score": 85,
        "peak_score": 115,
        "min_score": 50,
        "buy_pct": 67,
        "price_change_pct": -0.0
      },
      "fundamentals": {
        "pe": 15.7,
        "rev_growth_pct": 10.5,
        "margin_pct": 30.0,
        "target_price": 408.47,
        "target_upside_pct": 55.7,
        "target_median": 400.0,
        "target_high": 605.0,
        "target_low": 270.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 1,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 3,
          "buy": 17,
          "hold": 15,
          "sell": 4,
          "strong_sell": 0,
          "total": 39
        },
        "distribution_shift": {
          "buy_pct_change": -2.6,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "ANF",
        "correlation": 0.76,
        "phase": "Coiling",
        "months_est": 10.6
      },
      "ai_thesis": "Adobe's stock presents a compelling contrarian opportunity trading 42% below its 52-week high amid overblown fears about GenAI disruption, when the company is actually well-positioned to integrate AI capabilities across its dominant Creative Cloud ecosystem rather than be displaced by it. The negative sentiment catalyst creating this entry point is misguided concern about competitive threats from Figma and Canva, while Adobe's entrenched enterprise relationships and comprehensive creative suite provide a stronger moat than markets currently recognize. With insider selling likely complete and retail sentiment turning bullish (87% StockTwits bullish), the risk/reward favors accumulation ahead of Adobe's next earnings cycle where AI integration progress should drive multiple re-expansion.",
      "scans_tracked": 13,
      "first_detected": "2026-02-13T12:44:21.031878",
      "hysteresis_note": "BUY pending (streak 7/2, conf 56)",
      "events": [],
      "checklist": {
        "Profitable": "pass",
        "Strong FCF": "pass",
        "Near 52w Lows": "pass",
        "Sector Panic": "pass",
        "Low PE": "pass",
        "No Dilution": "pass"
      },
      "checklist_score": 6,
      "quality_framework": "value",
      "convergence_signal": true,
      "satellite_fit": 0.77,
      "satellite_score": 27,
      "entry_timing": {
        "score": 74,
        "label": "Wait",
        "recommended_entry": 265.69,
        "rsi": 39.9,
        "risk_reward": null,
        "entry_aging": "stale"
      }
    },
    {
      "ticker": "NBIS",
      "score": 90,
      "recommendation": "WATCHLIST",
      "profile": "recovery",
      "tier": 2,
      "confidence": 97,
      "price": 91.19,
      "market_cap_fmt": "$23.1B",
      "down_from_high_pct": 35.4,
      "catalyst_type": "earnings",
      "catalyst_date": "2026-05-18",
      "days_to_catalyst": 79,
      "short_interest_pct": 18.09,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "catalyst": 20,
        "fallen_angel": 15,
        "fundamental": 20,
        "social": 15,
        "news_boost": 9,
        "acceleration_influence": -7,
        "breakout_pattern_bonus": 6,
        "fundamental_risk": -11,
        "claude_enhancement": 1,
        "ai_disruption": 18
      },
      "score_trend": [
        79,
        47,
        69,
        39,
        52,
        47,
        47,
        47,
        47,
        90
      ],
      "price_trend": [
        97.92,
        97.92,
        97.92,
        100.61,
        102.136,
        102.136,
        102.58,
        104.88,
        104.88,
        91.19
      ],
      "trend_direction": "improving",
      "aggregate": {
        "avg_score": 53,
        "peak_score": 90,
        "min_score": 39,
        "buy_pct": 11,
        "price_change_pct": 2.9
      },
      "fundamentals": {
        "pe": 759.9,
        "rev_growth_pct": 5.0,
        "margin_pct": 19.2,
        "target_price": 147.45,
        "target_upside_pct": 61.7,
        "target_median": 150.0,
        "target_high": 232.0,
        "target_low": 70.0
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 2,
          "buy": 7,
          "hold": 2,
          "sell": 0,
          "strong_sell": 1,
          "total": 12
        },
        "distribution_shift": {
          "buy_pct_change": 5.0,
          "sell_pct_change": 8.3
        }
      },
      "trajectory": {},
      "ai_thesis": "NBIS presents a compelling buy opportunity with its transformative AI acquisition expected to materialize within 79 days, positioning the company to capitalize on the rapidly expanding AI cloud infrastructure market. Trading 35% below its 52-week high at $91.19, the stock offers an attractive entry point despite overwhelmingly bullish sentiment (89% on StockTwits), suggesting the market hasn't fully priced in the acquisition's potential impact on Nebius's AI cloud business growth trajectory. The combination of a concrete near-term catalyst, discounted valuation, and strong retail sentiment creates an asymmetric risk-reward setup for investors willing to position ahead of the acquisition completion.",
      "scans_tracked": 10,
      "first_detected": "2026-02-12T09:32:03.067211",
      "hysteresis_note": "BUY pending (streak 1/2, conf 97)",
      "events": [],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 1.03,
      "satellite_score": 53,
      "entry_timing": {
        "score": 82,
        "label": "Enter",
        "recommended_entry": 93.85,
        "rsi": 45.9,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "TTD",
      "score": 89,
      "recommendation": "WATCHLIST",
      "profile": "value",
      "tier": 5,
      "confidence": 56,
      "price": 23.82,
      "market_cap_fmt": "$11.6B",
      "down_from_high_pct": 74.0,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 10.61,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "profitability": 18,
        "fcf": 13,
        "discount": 8,
        "sector_panic": 15,
        "pe_discount": 15,
        "no_dilution": 11,
        "convergence_bonus": 8,
        "news_boost": 6,
        "breakout_pattern_bonus": 14,
        "claude_enhancement": -5,
        "ai_disruption": 8
      },
      "score_trend": [
        92,
        84,
        83,
        84,
        89
      ],
      "price_trend": [
        25.5,
        25.16,
        23.95,
        23.95,
        23.82
      ],
      "trend_direction": "improving",
      "aggregate": {
        "avg_score": 86,
        "peak_score": 92,
        "min_score": 83,
        "buy_pct": 100,
        "price_change_pct": -6.6
      },
      "fundamentals": {
        "pe": 27.1,
        "rev_growth_pct": 14.3,
        "margin_pct": 15.3,
        "target_price": 34.98,
        "target_upside_pct": 46.9,
        "target_median": 32.0,
        "target_high": 70.0,
        "target_low": 17.0
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 3,
          "buy": 16,
          "hold": 15,
          "sell": 3,
          "strong_sell": 1,
          "total": 38
        },
        "distribution_shift": {
          "buy_pct_change": -2.6,
          "sell_pct_change": 2.6
        }
      },
      "trajectory": {
        "match": "HIMS",
        "correlation": 0.77,
        "phase": "Launch Ready",
        "months_est": 5.3
      },
      "ai_thesis": "TTD has been oversold following its Q4 earnings beat due to conservative Q1 2026 guidance (10% vs 12% expected growth), creating an opportunistic entry point at $23.82, which represents a 74% discount from its 52-week high despite the company's fundamentals remaining intact. The market overreaction to modest guidance conservatism, combined with overwhelmingly bullish retail sentiment (89% on StockTwits) and a strong fundamental score of 107/100, suggests the stock is primed for a technical bounce as investors recognize the disconnect between the solid Q4 performance and the excessive sell-off. This presents an immediate buying opportunity to capitalize on the sentiment-driven dislocation before the market re-rates the stock higher on its proven execution capabilities.",
      "scans_tracked": 4,
      "first_detected": "2026-02-19T08:39:27.100537",
      "hysteresis_note": "BUY pending (streak 3/2, conf 56)",
      "events": [],
      "checklist": {
        "Profitable": "pass",
        "Strong FCF": "pass",
        "Near 52w Lows": "partial",
        "Sector Panic": "pass",
        "Low PE": "pass",
        "No Dilution": "pass"
      },
      "checklist_score": 5,
      "quality_framework": "value",
      "convergence_signal": true,
      "satellite_fit": 1.09,
      "satellite_score": 59,
      "entry_timing": {
        "score": 80,
        "label": "Enter",
        "recommended_entry": 26.27,
        "rsi": 25.9,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "AGI",
      "score": 80,
      "recommendation": "WATCHLIST",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 53,
      "price": 54.19,
      "market_cap_fmt": "$22.8B",
      "down_from_high_pct": 0.3,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": null,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 20,
        "gross_margins_q": 15,
        "nrr": 6,
        "tam": 5,
        "rule40": 20,
        "sbc": 15,
        "convergence_bonus": 8,
        "news_boost": 4,
        "breakout_pattern_bonus": 14,
        "claude_enhancement": 3,
        "ai_disruption": 1,
        "narrative_overlap": -1,
        "low_upside": -10
      },
      "score_trend": [
        78,
        78,
        78,
        78,
        80,
        79,
        77,
        80
      ],
      "price_trend": [
        49.7,
        50.52,
        50.52,
        50.56,
        50.02,
        52.45,
        52.45,
        54.19
      ],
      "trend_direction": "stable",
      "aggregate": {
        "avg_score": 78,
        "peak_score": 80,
        "min_score": 77,
        "buy_pct": 100,
        "price_change_pct": 9.0
      },
      "fundamentals": {
        "pe": 25.8,
        "rev_growth_pct": 53.1,
        "margin_pct": 49.0,
        "target_price": 56.5,
        "target_upside_pct": 4.3,
        "target_median": 58.5,
        "target_high": 61.0,
        "target_low": 48.0
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 5,
          "buy": 8,
          "hold": 0,
          "sell": 0,
          "strong_sell": 0,
          "total": 13
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "PLTR_2025-05-05",
        "correlation": 0.78,
        "phase": "Launch Ready",
        "months_est": 5.1
      },
      "ai_thesis": "AGI presents a compelling buy opportunity following its record earnings beat and 17% dividend hike, which catalyzed a 17% surge while demonstrating the company's strong cash generation capabilities at current gold prices. With the stock now trading at 52-week highs amid 100% bullish sentiment on StockTwits and a stellar +0.67 news sentiment score, momentum remains firmly positive as investors recognize AGI's operational excellence and shareholder-friendly capital allocation. The immediate post-earnings momentum, combined with gold's continued strength and AGI's proven ability to generate excess cash flow for dividend growth, positions the stock for continued outperformance as institutional investors likely increase allocations following this fundamental inflection point.",
      "scans_tracked": 5,
      "first_detected": "2026-02-24T08:47:30.254517",
      "hysteresis_note": "BUY pending (streak 4/2, conf 53)",
      "events": [],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "partial",
        "TAM Opportunity": "partial",
        "Rule of 40": "pass",
        "Low SBC": "pass"
      },
      "checklist_score": 4,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 1.08,
      "satellite_score": 0,
      "entry_timing": {
        "score": 5,
        "label": "Stretched",
        "recommended_entry": 44.54,
        "rsi": 70.1,
        "risk_reward": 0.19,
        "entry_aging": ""
      }
    },
    {
      "ticker": "BRCTF",
      "score": 79,
      "recommendation": "WATCHLIST",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 71,
      "price": 38.06,
      "market_cap_fmt": "$3.4B",
      "down_from_high_pct": 0,
      "catalyst_type": "fda",
      "catalyst_date": "2026-05-24",
      "days_to_catalyst": 85,
      "short_interest_pct": null,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 20,
        "gross_margins_q": 20,
        "nrr": 6,
        "tam": 8,
        "rule40": 20,
        "sbc": 5,
        "convergence_bonus": 8,
        "news_boost": 3,
        "breakout_pattern_bonus": 4,
        "claude_enhancement": 3,
        "ai_disruption": 2
      },
      "score_trend": [
        79
      ],
      "price_trend": [
        38.06
      ],
      "trend_direction": "new",
      "aggregate": {},
      "fundamentals": {
        "pe": 30.4,
        "rev_growth_pct": 81.8,
        "margin_pct": 51.1
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {},
      "trajectory": {},
      "ai_thesis": "BioArctic represents a compelling buy opportunity ahead of the expected EU regulatory approval for lecanemab within the next 85 days, following the positive CHMP recommendation that positions the company for transformative partnership deals similar to their existing Roche agreement. With the stock trading at 52-week highs and 100% bullish sentiment on StockTwits, the market is recognizing the imminent value inflection from what could be Europe's first approved Alzheimer's treatment. The regulatory catalyst timeline provides a clear 3-month window for significant upside as partnership valuations typically expand dramatically post-approval in the multi-billion dollar dementia treatment market.",
      "scans_tracked": 1,
      "first_detected": "2026-02-28T07:34:43.953023",
      "hysteresis_note": "BUY pending (streak 1/2, conf 71)",
      "events": [],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "partial",
        "TAM Opportunity": "pass",
        "Rule of 40": "pass",
        "Low SBC": "partial"
      },
      "checklist_score": 4,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 1.2,
      "satellite_score": 70,
      "entry_timing": {
        "score": 18,
        "label": "Stretched",
        "recommended_entry": 35.28,
        "rsi": 81.8,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "GDDY",
      "score": 78,
      "recommendation": "WATCHLIST",
      "profile": "value",
      "tier": 5,
      "confidence": 56,
      "price": 87.16,
      "market_cap_fmt": "$12.1B",
      "down_from_high_pct": 55.0,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 6.11,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "profitability": 20,
        "fcf": 20,
        "discount": 15,
        "sector_panic": 15,
        "pe_discount": 15,
        "no_dilution": 8,
        "convergence_bonus": 8,
        "news_boost": 7,
        "breakout_pattern_bonus": 13,
        "fundamental_risk": -4,
        "claude_enhancement": -8,
        "ai_disruption": 3,
        "insider_sell_penalty": -15
      },
      "score_trend": [
        103,
        82,
        67,
        70,
        70,
        68,
        78,
        65,
        76,
        78
      ],
      "price_trend": [
        90.64,
        90.64,
        87.76,
        92.725,
        92.725,
        92.3,
        79.12,
        86.2,
        86.2,
        87.16
      ],
      "trend_direction": "improving",
      "aggregate": {
        "avg_score": 84,
        "peak_score": 111,
        "min_score": 65,
        "buy_pct": 64,
        "price_change_pct": -3.7
      },
      "fundamentals": {
        "pe": 15.0,
        "rev_growth_pct": 6.8,
        "margin_pct": 17.7,
        "target_price": 124.79,
        "target_upside_pct": 43.2,
        "target_median": 102.5,
        "target_high": 200.0,
        "target_low": 77.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 9,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 3,
          "buy": 6,
          "hold": 7,
          "sell": 0,
          "strong_sell": 0,
          "total": 16
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "GPCR",
        "correlation": 0.77,
        "phase": "Coiling",
        "months_est": 7.9
      },
      "ai_thesis": "GoDaddy's 14-21% post-earnings selloff creating the S&P 500's worst performer presents an exceptional contrarian entry at $87.16, trading 55% below its 52-week high despite beating earnings expectations. The market's overreaction to softer revenue guidance has created a technical oversold condition while retail sentiment remains overwhelmingly bullish at 80%, suggesting institutional selling has run its course and a relief rally is imminent. With a strong score of 113/100 indicating fundamental resilience beneath the guidance disappointment, this represents a classic \"sell the news\" opportunity where patient investors can capitalize on temporary sentiment disconnects.",
      "scans_tracked": 7,
      "first_detected": "2026-02-18T23:11:02.121941",
      "hysteresis_note": "BUY pending (streak 1/2, conf 56)",
      "events": [],
      "checklist": {
        "Profitable": "pass",
        "Strong FCF": "pass",
        "Near 52w Lows": "pass",
        "Sector Panic": "pass",
        "Low PE": "pass",
        "No Dilution": "partial"
      },
      "checklist_score": 5,
      "quality_framework": "value",
      "convergence_signal": true,
      "satellite_fit": 1.2,
      "satellite_score": 70,
      "entry_timing": {
        "score": 81,
        "label": "Enter",
        "recommended_entry": 91.98,
        "rsi": 39.9,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "IREN",
      "score": 74,
      "recommendation": "WATCHLIST",
      "profile": "recovery",
      "tier": 2,
      "confidence": 95,
      "price": 40.95,
      "market_cap_fmt": "$13.6B",
      "down_from_high_pct": 46.7,
      "catalyst_type": "earnings",
      "catalyst_date": "2026-05-12",
      "days_to_catalyst": 73,
      "short_interest_pct": 13.09,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "catalyst": 20,
        "fallen_angel": 22,
        "fundamental": 20,
        "social": 15,
        "news_boost": 7,
        "breakout_pattern_bonus": 3,
        "quality_persistence": -2,
        "fundamental_risk": -3,
        "claude_enhancement": 1,
        "ai_disruption": 15,
        "thesis_feedback": -20
      },
      "score_trend": [
        72,
        82,
        81,
        95,
        95,
        79,
        92,
        92,
        92,
        74
      ],
      "price_trend": [
        39.98,
        39.9966,
        42.36,
        44.49,
        44.49,
        45.45,
        44.03,
        44.24,
        44.24,
        40.95
      ],
      "trend_direction": "declining",
      "aggregate": {
        "avg_score": 79,
        "peak_score": 95,
        "min_score": 64,
        "buy_pct": 74,
        "price_change_pct": 2.3
      },
      "fundamentals": {
        "pe": 28.4,
        "rev_growth_pct": 59.0,
        "margin_pct": 51.5,
        "target_price": 79.31,
        "target_upside_pct": 93.7,
        "target_median": 80.0,
        "target_high": 125.0,
        "target_low": 37.0
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {
        "signal": "MODERATE",
        "buyers": 2,
        "bipartisan": true
      },
      "analyst": {
        "distribution": {
          "strong_buy": 1,
          "buy": 10,
          "hold": 2,
          "sell": 0,
          "strong_sell": 1,
          "total": 14
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {},
      "ai_thesis": "IREN presents a compelling buy opportunity ahead of its expected MSCI index inclusion in approximately 73 days, which should drive significant passive fund inflows following Cantor Fitzgerald's recent $126M institutional investment positioning the company as an AI infrastructure play. Trading 47% below its 52-week high at $40.95 despite strong bullish sentiment (85% on StockTwits), the current price offers an attractive entry point before institutional buying pressure from index inclusion drives the stock higher. The combination of discounted valuation, upcoming forced buying from index funds, and validated institutional interest creates a clear catalyst-driven setup with defined timing.",
      "scans_tracked": 17,
      "first_detected": "2026-02-13T08:58:21.171632",
      "hysteresis_note": "",
      "events": [],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 1.09,
      "satellite_score": 59,
      "entry_timing": {
        "score": 61,
        "label": "Wait",
        "recommended_entry": 44.26,
        "rsi": 43.5,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "PYPL",
      "score": 73,
      "recommendation": "WATCHLIST",
      "profile": "value",
      "tier": 5,
      "confidence": 49,
      "price": 46.21,
      "market_cap_fmt": "$43.2B",
      "down_from_high_pct": 41.9,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 5.63,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "profitability": 20,
        "fcf": 16,
        "discount": 15,
        "sector_panic": 15,
        "pe_discount": 11,
        "no_dilution": 13,
        "convergence_bonus": 8,
        "news_boost": 9,
        "breakout_pattern_bonus": 11,
        "fundamental_risk": -7,
        "claude_enhancement": -2,
        "ai_disruption": 2,
        "insider_sell_penalty": -10,
        "low_upside": -10
      },
      "score_trend": [
        98,
        65,
        76,
        78,
        80,
        74,
        72,
        73,
        67,
        73
      ],
      "price_trend": [
        41.65,
        41.65,
        44.05,
        43.425,
        43.425,
        47.02,
        47.32,
        45.53,
        45.53,
        46.21
      ],
      "trend_direction": "stable",
      "aggregate": {
        "avg_score": 83,
        "peak_score": 105,
        "min_score": 47,
        "buy_pct": 65,
        "price_change_pct": -11.7
      },
      "fundamentals": {
        "pe": 8.5,
        "rev_growth_pct": 3.7,
        "margin_pct": 15.8,
        "target_price": 51.88,
        "target_upside_pct": 12.3,
        "target_median": 47.0,
        "target_high": 100.0,
        "target_low": 32.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 4,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 2,
          "buy": 8,
          "hold": 31,
          "sell": 4,
          "strong_sell": 0,
          "total": 45
        },
        "distribution_shift": {
          "buy_pct_change": -6.7,
          "sell_pct_change": -2.2
        }
      },
      "trajectory": {
        "match": "UBER",
        "correlation": 0.76,
        "phase": "Coiling",
        "months_est": 10.8
      },
      "ai_thesis": "PayPal's strategic partnership with MoonPay to launch PYUSDx positions the company at the forefront of the rapidly expanding stablecoin infrastructure market, offering significant revenue diversification beyond traditional payment processing. Trading 42% below its 52-week high at $46.21, PYPL presents an attractive entry point with 100% bullish StockTwits sentiment and a catalyst score of 111/100, suggesting the market hasn't fully priced in this crypto expansion opportunity. Despite negative insider activity, the technical dislocation combined with this transformative partnership creates an asymmetric risk-reward setup for investors willing to capitalize on PayPal's digital currency pivot.",
      "scans_tracked": 8,
      "first_detected": "2026-02-03T06:43:01.944105+00:00",
      "hysteresis_note": "",
      "events": [],
      "checklist": {
        "Profitable": "pass",
        "Strong FCF": "pass",
        "Near 52w Lows": "pass",
        "Sector Panic": "pass",
        "Low PE": "pass",
        "No Dilution": "pass"
      },
      "checklist_score": 6,
      "quality_framework": "value",
      "convergence_signal": true,
      "satellite_fit": 1.2,
      "satellite_score": 0,
      "entry_timing": {
        "score": 42,
        "label": "Wait",
        "recommended_entry": 43.32,
        "rsi": 48.4,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "PLTR",
      "score": 66,
      "recommendation": "WATCHLIST",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 82,
      "price": 137.19,
      "market_cap_fmt": "$328.1B",
      "down_from_high_pct": 33.9,
      "catalyst_type": "analyst",
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 2.35,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 20,
        "gross_margins_q": 20,
        "nrr": 10,
        "tam": 2,
        "rule40": 20,
        "sbc": 0,
        "convergence_bonus": 8,
        "news_boost": 8,
        "breakout_pattern_bonus": 8,
        "fundamental_risk": -8,
        "claude_enhancement": -1,
        "ai_disruption": 18,
        "insider_sell_penalty": -25
      },
      "score_trend": [
        66,
        65,
        49,
        62,
        63,
        62,
        66,
        66,
        66,
        66
      ],
      "price_trend": [
        135.24,
        135.24,
        130.6,
        129.332,
        129.332,
        128.84,
        134.19,
        135.94,
        135.94,
        137.19
      ],
      "trend_direction": "stable",
      "aggregate": {
        "avg_score": 61,
        "peak_score": 79,
        "min_score": 43,
        "buy_pct": 9,
        "price_change_pct": -7.2
      },
      "fundamentals": {
        "pe": 217.8,
        "rev_growth_pct": 70.0,
        "margin_pct": 36.3,
        "target_price": 184.49,
        "target_upside_pct": 34.5,
        "target_median": 192.5,
        "target_high": 260.0,
        "target_low": 70.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 63,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 1,
          "buy": 15,
          "hold": 10,
          "sell": 1,
          "strong_sell": 1,
          "total": 28
        },
        "distribution_shift": {
          "buy_pct_change": 31.2,
          "sell_pct_change": -7.7
        }
      },
      "trajectory": {
        "match": "LITE",
        "correlation": 0.72,
        "phase": "Accumulation",
        "months_est": 14.0
      },
      "ai_thesis": "PLTR's new partnership with Innodata for AI data engineering services to the U.S. Missile Defense Agency validates its expanding defense AI capabilities and should drive near-term revenue acceleration as these high-value government contracts scale. At 34% below its 52-week high despite 92% bullish sentiment on StockTwits, the stock presents an attractive entry point with technical oversold conditions creating upside potential as partnership momentum builds. The collaboration positions PLTR to capture more defense AI spending while demonstrating commercial scalability of its data platforms beyond traditional government analytics contracts.",
      "scans_tracked": 12,
      "first_detected": "2026-02-03T06:49:57.002264+00:00",
      "hysteresis_note": "",
      "events": [
        {
          "type": "analyst_upgrade",
          "date": null,
          "summary": "Palantir upgraded to Outperform from Neutral by Mizuho with $195 price target amid AI partnership and defense contract.",
          "direction": "bull"
        }
      ],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "pass",
        "TAM Opportunity": "fail",
        "Rule of 40": "pass",
        "Low SBC": "fail"
      },
      "checklist_score": 4,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 0.6,
      "satellite_score": 10,
      "entry_timing": {
        "score": 55,
        "label": "Wait",
        "recommended_entry": 137.08,
        "rsi": 43.0,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "DSKYF",
      "score": 64,
      "recommendation": "MOMENTUM",
      "profile": "recovery",
      "tier": 2,
      "confidence": 47,
      "price": 19.53,
      "market_cap_fmt": "$36.1B",
      "down_from_high_pct": 33.0,
      "catalyst_type": "fda",
      "catalyst_date": "2026-06-02",
      "days_to_catalyst": 94,
      "short_interest_pct": null,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "catalyst": 20,
        "fallen_angel": 20,
        "fundamental": 20,
        "social": 0,
        "news_boost": 0,
        "breakout_pattern_bonus": 20,
        "fundamental_risk": 5,
        "claude_enhancement": -8,
        "ai_disruption": 3
      },
      "score_trend": [
        64
      ],
      "price_trend": [
        19.53
      ],
      "trend_direction": "new",
      "aggregate": {},
      "fundamentals": {
        "pe": 20.3,
        "rev_growth_pct": 15.1,
        "margin_pct": 14.8
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {},
      "trajectory": {
        "match": "HIMS",
        "correlation": 0.75,
        "phase": "Launch Ready",
        "months_est": 5.4
      },
      "ai_thesis": "DSKYF presents a compelling buy opportunity ahead of its FDA catalyst in 94 days, with shares trading 33% below 52-week highs at $19.53, creating an attractive risk-reward setup for the regulatory decision. The neutral market sentiment (50% bullish on StockTwits) and lack of recent insider activity suggests the FDA outcome is not yet priced in, providing upside potential if approval is granted. With a strong score of 77/100 and the stock trading at technically oversold levels, current prices offer an optimal entry point before potential FDA-driven momentum.",
      "scans_tracked": 1,
      "first_detected": "2026-02-28T07:34:43.904334",
      "hysteresis_note": "",
      "events": [],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 0.99,
      "satellite_score": 49,
      "entry_timing": {
        "score": 27,
        "label": "Stretched",
        "recommended_entry": 18.93,
        "rsi": 50.2,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "SOFI",
      "score": 62,
      "recommendation": "MOMENTUM",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 48,
      "price": 17.76,
      "market_cap_fmt": "$22.6B",
      "down_from_high_pct": 45.7,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 9.78,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 15,
        "gross_margins_q": 20,
        "nrr": 6,
        "tam": 5,
        "rule40": 15,
        "sbc": 10,
        "convergence_bonus": 8,
        "momentum_bonus": 9,
        "breakout_pattern_bonus": 11,
        "fundamental_risk": -3,
        "claude_enhancement": -6,
        "ai_disruption": 3,
        "controversy_penalty": -5,
        "controversy_insider_compound": -10
      },
      "score_trend": [
        52,
        0,
        58,
        70,
        72,
        66,
        74,
        72,
        77,
        62
      ],
      "price_trend": [
        19.3,
        19.695,
        18.22,
        18.43,
        18.43,
        18.66,
        19.29,
        19.1,
        19.1,
        17.76
      ],
      "trend_direction": "declining",
      "aggregate": {
        "avg_score": 62,
        "peak_score": 78,
        "min_score": 0,
        "buy_pct": 18,
        "price_change_pct": -22.1
      },
      "fundamentals": {
        "pe": 45.5,
        "rev_growth_pct": 40.2,
        "margin_pct": 13.4,
        "target_price": 26.5,
        "target_upside_pct": 49.2,
        "target_median": 26.0,
        "target_high": 38.0,
        "target_low": 12.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 2,
        "sells": 5,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 3,
          "buy": 5,
          "hold": 10,
          "sell": 2,
          "strong_sell": 2,
          "total": 22
        },
        "distribution_shift": {
          "buy_pct_change": 9.1,
          "sell_pct_change": -4.5
        }
      },
      "trajectory": {
        "match": "ANF",
        "correlation": 0.72,
        "phase": "Coiling",
        "months_est": 11.2
      },
      "ai_thesis": "SOFI presents a compelling buy opportunity at $17.76, trading 46% below its 52-week high with neutral sentiment creating an optimal contrarian entry point ahead of the Federal Reserve's anticipated rate cutting cycle in 2024. The company's diversified fintech platform is positioned to benefit significantly from lower interest rates, which will reduce funding costs and stimulate loan origination growth, while the current depressed valuation and muted investor enthusiasm provide substantial upside as rate cuts materialize over the next 6-12 months. With a strong score of 92/100 and shares at multi-month lows, this represents an asymmetric risk-reward setup before the market reprices SOFI's earnings power in a lower rate environment.",
      "scans_tracked": 7,
      "first_detected": "2026-01-31T10:03:06.647236+00:00",
      "hysteresis_note": "",
      "events": [],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "partial",
        "TAM Opportunity": "partial",
        "Rule of 40": "pass",
        "Low SBC": "pass"
      },
      "checklist_score": 4,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 1.09,
      "satellite_score": 59,
      "entry_timing": {
        "score": 80,
        "label": "Enter",
        "recommended_entry": 20.01,
        "rsi": 28.5,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "CRWV",
      "score": 55,
      "recommendation": "MOMENTUM",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 87,
      "price": 79.56,
      "market_cap_fmt": "$41.5B",
      "down_from_high_pct": 57.5,
      "catalyst_type": "earnings",
      "catalyst_date": "2026-05-15",
      "days_to_catalyst": 76,
      "short_interest_pct": 18.86,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 20,
        "gross_margins_q": 15,
        "nrr": 10,
        "tam": 2,
        "rule40": 20,
        "sbc": 10,
        "convergence_bonus": 8,
        "news_boost": 5,
        "momentum_bonus": 7,
        "breakout_pattern_bonus": 8,
        "claude_enhancement": -10,
        "ai_disruption": 18,
        "controversy_penalty": -5,
        "low_margin": -10,
        "insider_sell_penalty": -25,
        "controversy_insider_compound": -10
      },
      "score_trend": [
        47,
        35,
        38,
        61,
        67,
        66,
        69,
        71,
        55,
        55
      ],
      "price_trend": [
        89.25,
        89.25,
        90.84,
        95.89,
        95.89,
        99.3,
        98.01,
        97.63,
        97.63,
        79.56
      ],
      "trend_direction": "declining",
      "aggregate": {
        "avg_score": 54,
        "peak_score": 71,
        "min_score": 35,
        "buy_pct": 0,
        "price_change_pct": -16.9
      },
      "fundamentals": {
        "rev_growth_pct": 110.3,
        "margin_pct": -22.7,
        "target_price": 124.7,
        "target_upside_pct": 56.7,
        "target_median": 120.0,
        "target_high": 251.0,
        "target_low": 41.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 771,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 2,
          "buy": 16,
          "hold": 11,
          "sell": 1,
          "strong_sell": 0,
          "total": 30
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "MU",
        "correlation": 0.72,
        "phase": "Launch Ready",
        "months_est": 5.0
      },
      "ai_thesis": "CoreWeave's 57% decline from 52-week highs following disappointing revenue guidance has created an oversized selloff that ignores the company's strong AI GPU demand fundamentals and growing backlog, presenting an attractive entry point ahead of earnings in 76 days. The stock's current oversold technical position at $79.56, combined with muted sentiment (50% bullish on StockTwits) and complete insider selling exhaustion (0 buys in 90 days), suggests maximum pessimism has been reached just as the AI infrastructure boom accelerates. This earnings miss catalyst has disconnected CRWV's valuation from its long-term positioning in the high-growth GPU cloud market, creating a compelling risk-reward setup for recovery into the next earnings cycle.",
      "scans_tracked": 8,
      "first_detected": "2026-02-13T12:44:21.032323",
      "hysteresis_note": "",
      "events": [],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "pass",
        "TAM Opportunity": "fail",
        "Rule of 40": "pass",
        "Low SBC": "pass"
      },
      "checklist_score": 5,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 1.03,
      "satellite_score": 53,
      "entry_timing": {
        "score": 62,
        "label": "Wait",
        "recommended_entry": 91.81,
        "rsi": 40.4,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "MNKD",
      "score": 50,
      "recommendation": "MOMENTUM",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 90,
      "price": 3.28,
      "market_cap_fmt": "$1.0B",
      "down_from_high_pct": 49.6,
      "catalyst_type": "fda",
      "catalyst_date": "2026-05-29",
      "days_to_catalyst": 90,
      "short_interest_pct": 8.66,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 15,
        "gross_margins_q": 15,
        "nrr": 6,
        "tam": 8,
        "rule40": 10,
        "sbc": 10,
        "convergence_bonus": 8,
        "news_boost": 9,
        "breakout_pattern_bonus": 8,
        "claude_enhancement": -10,
        "ai_disruption": 2,
        "low_margin": -10,
        "insider_sell_penalty": -15
      },
      "score_trend": [
        50
      ],
      "price_trend": [
        3.28
      ],
      "trend_direction": "new",
      "aggregate": {},
      "fundamentals": {
        "pe": 32.8,
        "rev_growth_pct": 45.8,
        "margin_pct": 1.7,
        "target_price": 8.5,
        "target_upside_pct": 159.1,
        "target_median": 8.0,
        "target_high": 10.0,
        "target_low": 7.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 6,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 1,
          "buy": 8,
          "hold": 0,
          "sell": 0,
          "strong_sell": 0,
          "total": 9
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {},
      "ai_thesis": "MannKind presents a compelling contrarian opportunity as the market has overreacted to United Therapeutics' competitive threat, driving shares 50% below highs to $3.28 despite the company's established Afrezza platform and potential for defensive partnerships within the next 90 days. The current pessimistic sentiment and negative insider activity have created an oversold technical setup, while the 67% bullish retail sentiment and +0.40 news sentiment suggest institutional selling has likely exhausted itself. With a catalyst timeline of 90 days for partnership developments and the stock trading at a steep discount to recent valuations, the risk-reward favors accumulation ahead of potential partnership announcements that could validate MNKD's competitive positioning against new market entrants.",
      "scans_tracked": 1,
      "first_detected": "2026-02-28T07:34:44.006768",
      "hysteresis_note": "",
      "events": [],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "partial",
        "TAM Opportunity": "pass",
        "Rule of 40": "partial",
        "Low SBC": "pass"
      },
      "checklist_score": 4,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 1.39,
      "satellite_score": 89,
      "entry_timing": {
        "score": 70,
        "label": "Wait",
        "recommended_entry": 5.35,
        "rsi": 19.0,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "ASTS",
      "score": 47,
      "recommendation": "MOMENTUM",
      "profile": "recovery",
      "tier": 2,
      "confidence": 98,
      "price": 79.19,
      "market_cap_fmt": "$30.1B",
      "down_from_high_pct": 39.0,
      "catalyst_type": "earnings",
      "catalyst_date": "2026-05-11",
      "days_to_catalyst": 72,
      "short_interest_pct": 19.58,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "catalyst": 20,
        "fallen_angel": 15,
        "fundamental": 15,
        "social": 15,
        "news_boost": 9,
        "acceleration_influence": -7,
        "pre_revenue_discount": -7,
        "claude_enhancement": -1,
        "ai_disruption": 2,
        "low_margin": -10,
        "low_upside": -10
      },
      "score_trend": [
        42,
        39,
        40,
        40,
        43,
        42,
        42,
        46,
        39,
        47
      ],
      "price_trend": [
        80.2,
        80.2,
        83.98,
        83.98,
        83.9,
        84.2,
        84.2,
        82.36,
        85.76,
        79.19
      ],
      "trend_direction": "stable",
      "aggregate": {
        "avg_score": 48,
        "peak_score": 66,
        "min_score": 39,
        "buy_pct": 0,
        "price_change_pct": -21.4
      },
      "fundamentals": {
        "rev_growth_pct": 12.4,
        "margin_pct": 0.0,
        "target_price": 80.39,
        "target_upside_pct": 1.5,
        "target_median": 81.25,
        "target_high": 137.0,
        "target_low": 43.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 3,
        "sells": 4,
        "key_insider_buying": true
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 0,
          "buy": 3,
          "hold": 5,
          "sell": 0,
          "strong_sell": 2,
          "total": 10
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {},
      "ai_thesis": "AST SpaceMobile secured a $30M SDA contract validating its satellite-communications technology for government use, providing near-term revenue and credibility as a space infrastructure provider. Strong social media momentum (445% Reddit velocity) and bullish sentiment (83% StockTwits) suggest retail conviction, with positive news coverage outweighing skepticism.",
      "scans_tracked": 20,
      "first_detected": "2026-02-10T20:25:59.438167",
      "hysteresis_note": "",
      "events": [
        {
          "type": "launch_window",
          "date": null,
          "summary": "AST SpaceMobile aims to launch between 45 and 60 satellites in 2026.",
          "direction": "bull"
        },
        {
          "type": "contract_award",
          "date": "2026-02-23",
          "summary": "AST SpaceMobile USA secured its first $30 million SDA prime contract for the Europa Track 2 Commercial Solutions program to support the military's transport layer of communications and data relay sate",
          "direction": "bull"
        },
        {
          "type": "satellite_deployment",
          "date": null,
          "summary": "AST SpaceMobile planning multi-launcher campaign with one orbital launch every one to two months during 2026, with BlueBird 7 scheduled for late February on New Glenn-3 mission.",
          "direction": "bull"
        },
        {
          "type": "launch",
          "date": "2026-02-23",
          "summary": "AST SpaceMobile's BlueBird 7 launch is scheduled for late February 2026 on the New Glenn-3 mission from Cape Canaveral Space Force Station.",
          "direction": "bull"
        },
        {
          "type": "launch",
          "date": "2026-06-30",
          "summary": "AST SpaceMobile targeting 45-60 satellite launches in 2026 with one orbital launch every one to two months on average.",
          "direction": "bull"
        },
        {
          "type": "mission_launch",
          "date": null,
          "summary": "AST SpaceMobile targeting launch of 45-60 satellites in 2026 with over $1 billion in contracted commercial revenue commitments.",
          "direction": "bull"
        },
        {
          "type": "government_contract",
          "date": null,
          "summary": "AST SpaceMobile secured a prime position on the US Missile Defense Agency's Shield program under a multi-year IDIQ contract for research, development, engineering, and operations.",
          "direction": "bull"
        },
        {
          "type": "product_development",
          "date": null,
          "summary": "AST SpaceMobile executing Block 2 satellite launches over next two quarters with target of launching 45-60 satellites in 2026.",
          "direction": "bull"
        },
        {
          "type": "launch_campaign",
          "date": null,
          "summary": "AST SpaceMobile plans a multi-launcher campaign with one orbital launch every one to two months on average throughout 2026.",
          "direction": "bull"
        },
        {
          "type": "business_update",
          "date": "2026-03-02",
          "summary": "AST SpaceMobile will hold a quarterly business update call on March 2, 2026 at 5 PM ET to address questions from retail and institutional shareholders regarding business and financial results.",
          "direction": "neutral"
        },
        {
          "type": "launch_window",
          "date": "2026-02-28",
          "summary": "AST SpaceMobile planned multi-launcher campaign with BlueBird 7 launch scheduled for late February 2026 on New Glenn-3 mission from Cape Canaveral Space Force Station.",
          "direction": "bull"
        },
        {
          "type": "mission_launch",
          "date": "2026-03-31",
          "summary": "AST SpaceMobile planning multi-launcher campaign with one orbital launch every one to two months on average during 2026, with BlueBird 7 scheduled for late February on New Glenn-3 mission.",
          "direction": "bull"
        },
        {
          "type": "contract_award",
          "date": null,
          "summary": "AST SpaceMobile secured a prime contract position on the US Missile Defense Agency's shield program as part of the Pentagon's Golden Dome defense strategy, providing eligibility for future task orders",
          "direction": "bull"
        },
        {
          "type": "launch",
          "date": null,
          "summary": "AST SpaceMobile plans Block 2 BlueBird satellite launches over the next two quarters in 2026.",
          "direction": "bull"
        }
      ],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 1.03,
      "satellite_score": 0,
      "entry_timing": {
        "score": 65,
        "label": "Wait",
        "recommended_entry": 92.06,
        "rsi": 41.3,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "AXSM",
      "score": 44,
      "recommendation": "MOMENTUM",
      "profile": "quality_growth",
      "tier": 6,
      "confidence": 92,
      "price": 163.89,
      "market_cap_fmt": "$8.4B",
      "down_from_high_pct": 14.4,
      "catalyst_type": "fda",
      "catalyst_date": "2026-04-30",
      "days_to_catalyst": 61,
      "short_interest_pct": 6.34,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_growth_q": 20,
        "gross_margins_q": 20,
        "nrr": 6,
        "tam": 8,
        "rule40": 0,
        "sbc": 5,
        "convergence_bonus": 8,
        "news_boost": 6,
        "breakout_pattern_bonus": 14,
        "claude_enhancement": -6,
        "ai_disruption": 2,
        "low_margin": -10,
        "insider_sell_penalty": -25
      },
      "score_trend": [
        44
      ],
      "price_trend": [
        163.89
      ],
      "trend_direction": "new",
      "aggregate": {},
      "fundamentals": {
        "rev_growth_pct": 65.0,
        "margin_pct": -28.7,
        "target_price": 222.47,
        "target_upside_pct": 35.7,
        "target_median": 220.0,
        "target_high": 260.0,
        "target_low": 198.82
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 13,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 3,
          "buy": 16,
          "hold": 1,
          "sell": 0,
          "strong_sell": 0,
          "total": 20
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "GE",
        "correlation": 0.79,
        "phase": "Accumulation",
        "months_est": 12.9
      },
      "ai_thesis": "AXSM presents a compelling buy opportunity ahead of its upcoming FDA catalyst in 61 days, with shares trading 14% below 52-week highs at $163.89 despite maintaining a strong 88/100 score well above the 75 buy threshold. The current pullback from recent highs, combined with positive market sentiment (71% bullish on StockTwits) and no recent insider selling pressure, creates an attractive entry point before the binary FDA decision that could drive significant upside in this $8.4B CNS-focused biotech. The risk-reward profile favors accumulation now given the discounted valuation relative to recent peaks and the proximity to a potentially value-inflecting regulatory milestone.",
      "scans_tracked": 1,
      "first_detected": "2026-02-28T07:34:43.958198",
      "hysteresis_note": "",
      "events": [],
      "checklist": {
        "Revenue Growth": "pass",
        "Gross Margins": "pass",
        "Net Retention": "partial",
        "TAM Opportunity": "pass",
        "Rule of 40": "fail",
        "Low SBC": "partial"
      },
      "checklist_score": 3,
      "quality_framework": "quality_growth",
      "convergence_signal": true,
      "satellite_fit": 1.33,
      "satellite_score": 83,
      "entry_timing": {
        "score": 66,
        "label": "Wait",
        "recommended_entry": 179.91,
        "rsi": 33.1,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "REPL",
      "score": 42,
      "recommendation": "MOMENTUM",
      "profile": "recovery",
      "tier": 1,
      "confidence": 49,
      "price": 7.65,
      "market_cap_fmt": "$632M",
      "down_from_high_pct": 42.2,
      "catalyst_type": "fda",
      "catalyst_date": "2026-04-10",
      "days_to_catalyst": 41,
      "short_interest_pct": 33.71,
      "squeeze_potential": true,
      "squeeze_reasons": [
        "SI 33.7% + catalyst + 11.3 days-to-cover"
      ],
      "breakdown": {
        "catalyst": 40,
        "social": 0,
        "technical": 8,
        "fundamental": 10,
        "news_boost": 0,
        "breakout_pattern_bonus": 8,
        "catalyst_pattern_bonus": 12,
        "catalyst_trajectory_phase": 0.896,
        "claude_enhancement": -8,
        "ai_disruption": 2,
        "low_margin": -10,
        "insider_sell_penalty": -10
      },
      "score_trend": [
        42
      ],
      "price_trend": [
        7.65
      ],
      "trend_direction": "new",
      "aggregate": {},
      "fundamentals": {
        "margin_pct": 0.0,
        "target_price": 12.86,
        "target_upside_pct": 68.1,
        "target_median": 12.0,
        "target_high": 19.0,
        "target_low": 10.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 2,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 1,
          "buy": 4,
          "hold": 2,
          "sell": 0,
          "strong_sell": 0,
          "total": 7
        },
        "distribution_shift": {
          "buy_pct_change": -3.6,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "PLTR_2025-05-05",
        "correlation": 0.74,
        "phase": "Coiling",
        "months_est": 10.5,
        "catalyst_match": "HIMS",
        "catalyst_correlation": 0.71,
        "catalyst_phase": "Catalyst Imminent",
        "catalyst_months": 1.2
      },
      "ai_thesis": "REPL presents a compelling BUY opportunity ahead of its FDA catalyst in 41 days, with shares trading 42% below 52-week highs at $7.65, creating an attractive risk-reward setup for potential regulatory approval upside. The current negative insider activity and neutral sentiment (50% bullish on StockTwits) have created a contrarian entry point where expectations appear reset, positioning investors ahead of what could be a significant catalyst-driven revaluation. With a strong BUY score of 84/100 and the stock deeply discounted from recent highs, the current price offers asymmetric upside potential if the FDA decision proves favorable over the next 6 weeks.",
      "scans_tracked": 1,
      "first_detected": "2026-02-28T07:34:43.964251",
      "hysteresis_note": "",
      "events": [],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 1.32,
      "satellite_score": 82,
      "entry_timing": {
        "score": 77,
        "label": "Enter",
        "recommended_entry": 7.76,
        "rsi": 45.5,
        "risk_reward": null,
        "entry_aging": ""
      }
    },
    {
      "ticker": "ETN",
      "score": 38,
      "recommendation": "MOMENTUM",
      "profile": "acceleration",
      "tier": 3,
      "confidence": 53,
      "price": 375.92,
      "market_cap_fmt": "$146.3B",
      "down_from_high_pct": 8.0,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 2.01,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_momentum": 8,
        "margin_expansion": 12,
        "price_trend": 12,
        "volume_expansion": 3,
        "conviction": 7,
        "social_discovery": 4,
        "breakout_pattern_bonus": 17,
        "claude_enhancement": -3,
        "ai_disruption": 2,
        "insider_sell_penalty": -5,
        "low_upside": -10
      },
      "score_trend": [
        41,
        41,
        33,
        37,
        37,
        37,
        34,
        34,
        34,
        38
      ],
      "price_trend": [
        373.38,
        373.38,
        373.38,
        377.205,
        377.205,
        374.56,
        373.53,
        374.59,
        374.59,
        375.92
      ],
      "trend_direction": "improving",
      "aggregate": {
        "avg_score": 42,
        "peak_score": 56,
        "min_score": 33,
        "buy_pct": 0,
        "price_change_pct": -1.3
      },
      "fundamentals": {
        "pe": 36.0,
        "rev_growth_pct": 13.1,
        "margin_pct": 14.9,
        "target_price": 407.52,
        "target_upside_pct": 8.4,
        "target_median": 413.5,
        "target_high": 545.0,
        "target_low": 321.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 1,
        "key_insider_buying": false
      },
      "congress": {
        "signal": "STRONG",
        "buyers": 4,
        "bipartisan": true
      },
      "analyst": {
        "distribution": {
          "strong_buy": 7,
          "buy": 15,
          "hold": 7,
          "sell": 0,
          "strong_sell": 1,
          "total": 30
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 3.3
        }
      },
      "trajectory": {
        "match": "COIN_2024-02-26",
        "correlation": 0.7,
        "phase": "Accumulation",
        "months_est": 12.0
      },
      "ai_thesis": "ETN is a large-cap industrial company with established market position and $146B market cap, suggesting operational stability. The stock is trading 8% below recent highs, potentially offering near-term value for value-oriented investors.",
      "scans_tracked": 7,
      "first_detected": "2026-02-18T21:55:00.608562",
      "hysteresis_note": "",
      "events": [
        {
          "type": "sector_outperformance",
          "date": null,
          "summary": "Eaton, an industrial equipment manufacturer, is showing strong technical setups as industrials sector outpaces tech in early 2026.",
          "direction": "bull"
        }
      ],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 0.77,
      "satellite_score": 0,
      "entry_timing": {
        "score": 36,
        "label": "Stretched",
        "recommended_entry": 374.01,
        "rsi": 56.7,
        "risk_reward": 1.09,
        "entry_aging": ""
      }
    },
    {
      "ticker": "DTE",
      "score": 38,
      "recommendation": "MOMENTUM",
      "profile": "acceleration",
      "tier": 3,
      "confidence": 22,
      "price": 148.24,
      "market_cap_fmt": "$30.8B",
      "down_from_high_pct": 4.1,
      "catalyst_type": null,
      "catalyst_date": null,
      "days_to_catalyst": null,
      "short_interest_pct": 2.29,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "revenue_momentum": 17,
        "margin_expansion": 7,
        "price_trend": 14,
        "volume_expansion": 3,
        "conviction": 4,
        "social_discovery": 7,
        "breakout_pattern_bonus": 17,
        "claude_enhancement": -3,
        "ai_disruption": 1,
        "low_margin": -10,
        "low_upside": -10
      },
      "score_trend": [
        34,
        40,
        32,
        32,
        34,
        36,
        36,
        36,
        36,
        38
      ],
      "price_trend": [
        142.62,
        145.03,
        145.85,
        144.04,
        144.04,
        146.09,
        146.02,
        146.59,
        146.59,
        148.24
      ],
      "trend_direction": "stable",
      "aggregate": {
        "avg_score": 40,
        "peak_score": 57,
        "min_score": 32,
        "buy_pct": 0,
        "price_change_pct": 4.2
      },
      "fundamentals": {
        "pe": 21.1,
        "rev_growth_pct": 28.9,
        "margin_pct": 9.2,
        "target_price": 151.5,
        "target_upside_pct": 2.2,
        "target_median": 152.0,
        "target_high": 168.0,
        "target_low": 139.0
      },
      "insider": {
        "signal": "NEUTRAL",
        "buys": 0,
        "sells": 0,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 1,
          "buy": 8,
          "hold": 8,
          "sell": 0,
          "strong_sell": 0,
          "total": 17
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {
        "match": "COIN_2025-05-19",
        "correlation": 0.71,
        "phase": "Launch Ready",
        "months_est": 5.6
      },
      "ai_thesis": "DTE Energy is a large-cap utility with stable fundamentals and only 4% drawdown from highs, suggesting relative resilience. The modest Reddit mention activity (65) indicates some retail interest without excessive hype.",
      "scans_tracked": 6,
      "first_detected": "2026-02-18T21:55:00.597346",
      "hysteresis_note": "",
      "events": [],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 0.73,
      "satellite_score": 0,
      "entry_timing": {
        "score": 9,
        "label": "Stretched",
        "recommended_entry": 140.91,
        "rsi": 75.7,
        "risk_reward": 0.25,
        "entry_aging": ""
      }
    },
    {
      "ticker": "BMRN",
      "score": 34,
      "recommendation": "MOMENTUM",
      "profile": "recovery",
      "tier": 1,
      "confidence": 63,
      "price": 61.73,
      "market_cap_fmt": "$11.9B",
      "down_from_high_pct": 16.0,
      "catalyst_type": "fda",
      "catalyst_date": "2026-02-28",
      "days_to_catalyst": 0,
      "short_interest_pct": 5.75,
      "squeeze_potential": false,
      "squeeze_reasons": [],
      "breakdown": {
        "catalyst": 40,
        "social": 0,
        "technical": 0,
        "fundamental": 5,
        "news_boost": 0,
        "breakout_pattern_bonus": 10,
        "catalyst_pattern_bonus": 10,
        "claude_enhancement": -5,
        "ai_disruption": 2,
        "thesis_decay": -14,
        "insider_sell_penalty": -5
      },
      "score_trend": [
        52,
        43,
        50,
        34
      ],
      "price_trend": [
        59.87,
        61.83,
        61.44,
        61.73
      ],
      "trend_direction": "declining",
      "aggregate": {
        "avg_score": 45,
        "peak_score": 52,
        "min_score": 34,
        "buy_pct": 0,
        "price_change_pct": 3.1
      },
      "fundamentals": {
        "pe": 22.9,
        "rev_growth_pct": 17.0,
        "margin_pct": 10.8,
        "target_price": 88.17,
        "target_upside_pct": 42.8,
        "target_median": 94.0,
        "target_high": 120.0,
        "target_low": 55.0
      },
      "insider": {
        "signal": "NEGATIVE",
        "buys": 0,
        "sells": 2,
        "key_insider_buying": false
      },
      "congress": {},
      "analyst": {
        "distribution": {
          "strong_buy": 4,
          "buy": 14,
          "hold": 6,
          "sell": 0,
          "strong_sell": 0,
          "total": 24
        },
        "distribution_shift": {
          "buy_pct_change": 0.0,
          "sell_pct_change": 0.0
        }
      },
      "trajectory": {},
      "ai_thesis": "BioMarin has a FDA decision catalyst on February 28, 2026, which could unlock significant upside if approved. The $11.86B market cap and current 16% pullback from highs may present a reasonable entry for a biotech with active pipeline advancement.",
      "scans_tracked": 3,
      "first_detected": "2026-02-14T17:17:32.483071",
      "hysteresis_note": "",
      "events": [
        {
          "type": "pdufa_date",
          "date": null,
          "summary": "BioMarin Pharmaceutical has a PDUFA target action date of February 28, 2026.",
          "direction": "neutral"
        },
        {
          "type": "pdufa_date",
          "date": "2026-02-28",
          "summary": "BioMarin Pharmaceutical has a PDUFA target action date of February 28, 2026.",
          "direction": "neutral"
        }
      ],
      "checklist": {},
      "checklist_score": 0,
      "quality_framework": "",
      "convergence_signal": false,
      "satellite_fit": 0.99,
      "satellite_score": 49,
      "entry_timing": {
        "score": 48,
        "label": "Wait",
        "recommended_entry": 60.08,
        "rsi": 59.0,
        "risk_reward": 8.38,
        "entry_aging": ""
      }
    }
  ],
  "paper_portfolio": {
    "stats": {
      "total_open": 0,
      "total_pending": 0,
      "total_closed": 0,
      "open_pnl_eur": 0,
      "closed_pnl_eur": 0,
      "total_pnl_eur": 0,
      "avg_open_return": 0,
      "avg_closed_return": 0,
      "win_rate": 0,
      "timing_correlation": null
    },
    "positions": []
  }
}